The biotech industry is notorious for its pop-and-drop nature, but it also offers opportunities for risk-tolerant investors. For instance, these three companies' stock prices have tumbled, and one could be worth buying.
In the following slideshow I explain why these high-flying biotech companies are losing some of their luster and whether investors should consider buying them, holding them, or selling them.
Todd Campbell owns shares of OvaScience. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
